Imperial College London


Faculty of MedicineDepartment of Surgery & Cancer

Clinical SL in Medical Oncology (Gynaecological Oncology)







Institute of Reproductive and Developmental BiologyHammersmith Campus





Jon Krell is a Senior Clinical Lecturer in Medical Oncology with a clinical focus on the systemic management of patients with gynaecological malignancies. He also has a specialist clinical interest in cancer genetics and hereditary malignancies, particularly those involving the BRCA gene and other genetic mutations. He qualified in medicine at Leeds University Medical School, where he also gained a first class honours degree in Pharmacology. After completion of junior doctor posts at St. James’ Hospital in Leeds and Guys and St. Thomas’ Hospitals in London, he undertook his training in oncology at Charing Cross and Hammersmith Hospitals in London.

Dr Krell’s PhD research was funded by the Medical Research Council and investigated the interplay between genetic mutations, DNA damage and the response to cancer therapeutics. His ongoing research programme focuses on cancer genetics, polygenic risk and the interface between germline and somatic mutations, especially related to TP53 and BRCA. He also has a strong interest in the role of tumour and circulating small non-coding RNAs as diagnostic, prognostic and predictive biomarkers and as therapeutic modalities. This focuses on the areas of gynaecological and pancreatic malignancies and there is a strong translational research element to his work. He is a prominent member of the translational research team within the Ovarian Cancer Action Centre and Cancer Research UK centre at Imperial College that aims to overcome resistance to current anti-cancer agents in ovarian cancer. Current investigator-led trials include the OCA-funded PROGRESS study that aims to determine the feasibility of using a cancer risk algorithm to guide the personalisation of cancer screening and prevention programmes, and a BRC funded collaborative trial with the ICR investigating the role of Mainstreaming genetic testing in the cancer clinic.

Dr Krell has published over 100 peer-reviewed papers in journals such as the Lancet Oncology, Genome Research, The Journal of Clinical Oncology and Blood and regularly presents new data from his research at major national and international conferences.



Lythgoe M, Julve M, Krell J, et al., 2021, Racial diversity and reporting in FDA registration trials for genitourinary (GU) cancers from 2006-20., Journal of Clinical Oncology, Vol:39, ISSN:0732-183X, Pages:22-22

Lythgoe MP, Krell J, Mahmoud S, et al., 2021, Development and economic trends in anticancer drugs licensed in the UK from 2015 to 2019, Drug Discovery Today, Vol:26, ISSN:1359-6446, Pages:301-307

Morgan RD, McNeish IA, Cook AD, et al., 2021, Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial, The Lancet Oncology, Vol:22, ISSN:1213-9432, Pages:277-288

Lythgoe M, Stebbing J, Pickford E, et al., 2020, 805 Safety and emerging evidence of immune modulation of the live biotherapeutic MRx0518 in the neoadjuvant setting for patients awaiting surgical removal of solid tumours, Journal for Immunotherapy of Cancer, Vol:8, ISSN:2051-1426, Pages:A481-A482

Limb C, Liu D, Veno M, et al., 2020, The role of circular RNAs in pancreatic ductal adenocarcinoma and biliary-tract cancers, Cancers, Vol:12, ISSN:2072-6694

More Publications